SG11202108832XA - Anti-ang2 antibody and use thereof - Google Patents

Anti-ang2 antibody and use thereof

Info

Publication number
SG11202108832XA
SG11202108832XA SG11202108832XA SG11202108832XA SG11202108832XA SG 11202108832X A SG11202108832X A SG 11202108832XA SG 11202108832X A SG11202108832X A SG 11202108832XA SG 11202108832X A SG11202108832X A SG 11202108832XA SG 11202108832X A SG11202108832X A SG 11202108832XA
Authority
SG
Singapore
Prior art keywords
ang2 antibody
ang2
antibody
Prior art date
Application number
SG11202108832XA
Inventor
Ju Ryoung Nam
Sang Soon Byun
Jongil Ko
Do-Yun Kim
Joo Hyoung Lee
Jung Min Ha
Cheonho Park
Eun-Ah Lee
Weon Sup Lee
Jin-San Yoo
Original Assignee
Pharmabcine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmabcine Inc filed Critical Pharmabcine Inc
Publication of SG11202108832XA publication Critical patent/SG11202108832XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202108832XA 2019-02-25 2020-02-25 Anti-ang2 antibody and use thereof SG11202108832XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190021812 2019-02-25
PCT/KR2020/002687 WO2020175886A1 (en) 2019-02-25 2020-02-25 Anti-ang2 antibody and use thereof

Publications (1)

Publication Number Publication Date
SG11202108832XA true SG11202108832XA (en) 2021-09-29

Family

ID=72239735

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108832XA SG11202108832XA (en) 2019-02-25 2020-02-25 Anti-ang2 antibody and use thereof

Country Status (9)

Country Link
US (1) US20220204603A1 (en)
EP (1) EP3932946A4 (en)
JP (1) JP7177284B2 (en)
KR (1) KR102527315B1 (en)
CN (1) CN113728004A (en)
AU (1) AU2020227580A1 (en)
CA (1) CA3131250A1 (en)
SG (1) SG11202108832XA (en)
WO (1) WO2020175886A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116003591B (en) * 2022-12-12 2023-09-19 三门峡市眼科医院 Ang-2 antibodies and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
MX2007004247A (en) * 2004-10-19 2007-06-12 Amgen Inc Angiopoietin-2 specific binding agents.
PL1838733T3 (en) * 2004-12-21 2012-02-29 Medimmune Ltd Antibodies directed to angiopoietin-2 and uses thereof
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
JO3182B1 (en) * 2009-07-29 2018-03-08 Regeneron Pharma High Affinity Human Antibodies to Human Angiopoietin-2
CN104169299B (en) * 2012-01-23 2018-06-05 瑞泽恩制药公司 Stabilized preparations containing anti-Ang-2 antibody
MX350248B (en) 2012-03-30 2017-08-31 Boehringer Ingelheim Int Ang2-binding molecules.
JOP20200236A1 (en) * 2012-09-21 2017-06-16 Regeneron Pharma Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
AU2014368695A1 (en) * 2013-12-20 2016-04-14 F. Hoffmann-La Roche Ag Combination therapy with an anti-ANG2 antibody and a CD40 agonist
AU2015256052A1 (en) * 2014-05-07 2016-11-10 Medimmune, Llc Methods of using anti-Ang2 antibodies
AR100270A1 (en) * 2014-05-19 2016-09-21 Lilly Co Eli ANTIBODIES ANG2
KR102143132B1 (en) * 2016-12-26 2020-08-10 기초과학연구원 Composition for Preventing or Treating of Ocular Diseases Comprising Anti-Ang2 Antibody
WO2018124582A1 (en) * 2016-12-26 2018-07-05 기초과학연구원 Composition for preventing and treating eye diseases including anti-ang2 antibody

Also Published As

Publication number Publication date
EP3932946A4 (en) 2023-03-22
EP3932946A1 (en) 2022-01-05
KR20200103572A (en) 2020-09-02
CA3131250A1 (en) 2020-09-03
KR102527315B1 (en) 2023-05-03
JP2022522195A (en) 2022-04-14
JP7177284B2 (en) 2022-11-22
AU2020227580A1 (en) 2021-09-30
WO2020175886A1 (en) 2020-09-03
US20220204603A1 (en) 2022-06-30
CN113728004A (en) 2021-11-30

Similar Documents

Publication Publication Date Title
EP3904386A4 (en) Antibody and use thereof
ZA202006904B (en) Anti-il-4r antibody and use thereof
IL268206A (en) Bcma-targeting antibody and use thereof
EP3797124A4 (en) Anti-ror1 antibody and use thereof
SG11202100746WA (en) Anti-tigit antibody and use thereof
EP3802612A4 (en) Anti-b7-h3 antibody and use thereof
ZA202006066B (en) Anti-hla-g antibodies and use thereof
EP3907240A4 (en) Anti-tnfr2 antibody and use thereof
SG11202104240TA (en) Cll1-targeting antibody and application thereof
IL289585A (en) Dll3-targeting antibodies and uses thereof
IL287816A (en) Antibody to tigit and use thereof
EP4036116A4 (en) Anti-vhh domain antibodies and use thereof
EP4032904A4 (en) Anti-alpha-hemolysin antibody and use thereof
EP3567054A4 (en) Anti-alpha-syn antibody and use thereof
IL287690A (en) Anti-hvem antibodies and use thereof
IL282707A (en) Anti-tim-3 antibodies and their use
IL282708A (en) Anti-tim-3 antibodies and their use
SG11202112112UA (en) Anti-galectin-9 antibodies and uses thereof
IL291027A (en) Anti-steap1 antibodies and uses thereof
IL289656A (en) Anti-tigit antibodies and application thereof
EP3699193A4 (en) Anti-vista antibody and use thereof
EP4067378A4 (en) Antibody against c-kit and use thereof
IL291546A (en) Anti-kir3dl3 antibodies and uses thereof
IL291550A (en) Anti-il-27 antibodies and uses thereof
IL291280A (en) Anti-cd371 antibodies and uses thereof